KabuDo

NASDAQ: AXON · Aerospace & Defense

Axon Enterprise, Inc.

Axon makes TASER energy devices, body and in-car cameras, drones and counter-drone systems, and the cloud software that ties them together — Axon Evidence, records, real-time operations, and AI tools — mainly for police and public safety agencies. 2025 revenue grew 33.5% to $2.78 billion, with software and services at 43% and annual recurring revenue at $1.3 billion. Heavy spending on R&D and sales produced a small operating loss. Growth continued in 2026: Q2 revenue rose 35%, and future contracted bookings reached $15.1 billion. In February 2026 Axon bought Carbyne, a 911 platform, for $625 million.

Last updated

Analysis last edited: October 10, 2026 · Financial data fetched: October 17, 2026 10:06 (SEC EDGAR) · Source 10-K filed: February 25, 2026

Built on10-K FY2025 · filed 2026-02-2510-Q (quarter ended 2026-09-30) · filed 2026-11-06

Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

01

At a glanceFrom SEC data

Eight headline measures, each placed among the companies covered on this site.

Revenue growth
32.5%

Higher than 95% of 372 non-financial companies

Average yearly growth over the years shown

Operating margin
-2.2%

Higher than 4% of 311 non-financial companies

Latest fiscal year (FY2025)

ROIC minus WACC
-13.3 pts

Higher than 2% of 311 non-financial companies

Return on capital above (or below) its estimated cost

Net debt ÷ EBITDA
4.9x

Higher than 87% of 304 non-financial companies

Below 0 means more cash than debt

Cash conversion
1.70x

Higher than 58% of 349 non-financial companies

Operating cash flow ÷ net income

Dividend raises
—

Years the dividend per share rose, of the last 5

P/E today
132.7x

Latest close 2026-11-04; trailing 12 months to 2026-09-30

Beta
1.35

Above 1 = moves more than the market

Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.

02

Valuation todayFrom SEC data

Price-based measures at the latest close, next to the same measures at the last fiscal year-end.

Share price$427.54close on 2026-11-04

Market cap$34.29B

P/E today
132.7x

At FY2025 year-end: 376.1x

Earnings: trailing 12 months to 2026-09-30

P/B today
10.6x

At FY2025 year-end: 14.0x

Book value at FY2025 year-end

EV/EBITDA today
1,631.4x

At FY2025 year-end: 2,189.4x

EBITDA for FY2025

FCF yield today
0.2%

At FY2025 year-end: 0.2%

Free cash flow for FY2025

Dividend yield today
—

Dividends per share for FY2025

“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.

03

What changed since last earningsFrom SEC data

The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.

Quarter ended Sep 30, 2026.

  • Revenue↑ +27.8%$711M → $909M (vs. a year earlier)
  • Operating margin↑ +4.9 pts-0.3% → 4.6% (vs. a year earlier)
  • Net income↑ $57M−$2M → $57M (vs. a year earlier)
  • Diluted EPS↑ $0.68$-0.03 → $0.68 (vs. a year earlier)
  • Cash↑ +144.1%$598M → $1.46B (vs. previous quarter-end)
  • Long-term debt↑ +65.6%$1.73B → $2.87B (vs. previous quarter-end)

Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.

From the earnings release of Aug 5, 2026.

Management outlook ↑ Raised

Raised 2026 revenue growth outlook to 32%–34% from 30%–32%. Source sentence
2026 Revenue: Axon expects full-year 2026 revenue growth in a range of 32% to 34%, an increase from 30% to 32% previously.

Key changes

  • Q2 revenue up 35% to $904M. Source sentence
    Axon delivered another record quarter, with revenue increasing 35% year over year to $904 million — our 10th consecutive quarter of revenue growth above 30%.
  • Future contracted bookings up 41% to $15.1B. Source sentence
    Forward indicators were equally strong, with future contracted bookings growing 41% year over year to $15.1 billion.

Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗

04

Company profileFrom SEC dataShow

Legal name
AXON ENTERPRISE, INC.
Headquarters
SCOTTSDALE, AZ
Incorporated in
Delaware
Fiscal year end
12/31
Exchange & ticker
NASDAQ: AXON
Industry
Aerospace & Defense
CIK
1069183

Workforce (as of FY2025 year-end)

  • Employees

    5,100

Source: Form 10-K (FY2025) cover page and business description

05

Earnings calendarFrom SEC dataShow

When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.

Next report

Q4 FY2026

Quarter end: December 2026. In past years, Q4 results were released 55–58 days after quarter end (Feb 24, 2026; Feb 25, 2025; Feb 27, 2024). No date has been announced in the sources this site uses.

Reporting pattern

  • Fiscal year ends around December 31.
  • Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
  • Earnings releases came 35–58 days after quarter end over the last 12 quarters.
QuarterQuarter endedEarnings release (8-K)Report filed (10-Q / 10-K)
Q3 FY2026Sep 30, 2026Nov 5, 2026 (+36 days)Nov 6, 2026 10-Q (+37 days)
Q2 FY2026Jun 30, 2026Aug 5, 2026 (+36 days)Aug 6, 2026 10-Q (+37 days)
Q1 FY2026Mar 31, 2026May 6, 2026 (+36 days)May 7, 2026 10-Q (+37 days)
Q4 FY2025Dec 31, 2025Feb 24, 2026 (+55 days)Feb 25, 2026 10-K (+56 days)
Q3 FY2025Sep 30, 2025Nov 4, 2025 (+35 days)Nov 5, 2025 10-Q (+36 days)
Q2 FY2025Jun 30, 2025Aug 4, 2025 (+35 days)Aug 5, 2025 10-Q (+36 days)
Q1 FY2025Mar 31, 2025May 7, 2025 (+37 days)May 7, 2025 10-Q (+37 days)
Q4 FY2024Dec 31, 2024Feb 25, 2025 (+56 days)Feb 28, 2025 10-K (+59 days)
Q3 FY2024Sep 30, 2024Nov 7, 2024 (+38 days)Nov 8, 2024 10-Q (+39 days)
Q2 FY2024Jun 30, 2024Aug 6, 2024 (+37 days)Aug 7, 2024 10-Q (+38 days)
Q1 FY2024Mar 31, 2024May 6, 2024 (+36 days)May 7, 2024 10-Q (+37 days)
Q4 FY2023Dec 31, 2023Feb 27, 2024 (+58 days)Feb 27, 2024 10-K (+58 days)

Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.

06

Flagship products & servicesSite analysis

  • Connected Devices

    TASER

    Examples: TASER 10 handles and cartridges

    $914M of 2025 revenue.

  • Connected Devices

    Personal Sensors

    Examples: Axon Body 4 cameras

    $397M.

  • Connected Devices

    Platform Solutions

    Examples: Axon Fleet in-car video, fixed cameras and ALPR, drones, Dedrone counter-drone, VR training

    $266M (+73%).

  • Software and Services

    Software

    Examples: Axon Evidence, Axon Records, Draft One, Axon Fusus, Axon Respond, Axon 911

    $1.20B.

From the FY2025 Form 10-K.

U.S. and worldwide share of flagship products/services

The filings reviewed give no market share figure for the company's products or services.

Reviewed: Form 10-K (FY2025) · Form 10-Q (quarter ended 2026-06-30)

07

Recent strategic focusSite analysis

FY2025 from the 10-K, and 2026 events from 8-Ks.

  1. Carbyne acquisition

    Acquired in February 2026 for a base price of $625.0M; Axon previously held about 11%.

    Source: Form 10-K (FY2025), Note 20

  2. Q2 2026 results

    Revenue $904M (+35%), net income $29M; full-year revenue growth outlook raised to 32–34%.

    Source: Q2 2026 shareholder letter

  3. Convertible notes

    Issued $1.15B of 0% convertible senior notes due 2031 in September 2026, alongside a credit agreement amendment.

    Source: 8-Ks filed 2026-09-15 and 2026-09-21

  4. Board changes

    Vivek Mohindra and Eiso Kant joined the board in July 2026.

    Source: 8-K filed 2026-07-10

Capex ÷ D&A (FY2025)

1.64x

Well above depreciation — expansion-stage investment

formulacapital expenditures ÷ depreciation & amortization

e.g.$136M ÷ $83M = 1.64x

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

R&D-to-revenue ratio (FY2025)

24.6%

formularesearch & development expense ÷ revenue × 100

e.g.$684M ÷ $2,780M × 100 = 24.6%

termsResearch & development (R&D) · Revenue (net sales)

M&A spend (6-year total)

$1.31B

Latest year: $647M

Cash-flow-statement spending on acquisitions, net of cash acquired

Where the money goes, over time

Unit: $M. Capex went from $73M in FY2020 to $136M in FY2025

  • Capex
  • R&D
  • M&A spend

formulacapital expenditures ÷ depreciation & amortization

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

08

Key figures at a glanceFrom SEC data

FY2020–FY2025, 6 years.

Revenue (FY2025)

$2.78B

As reported in the 10-K

Revenue CAGR (5 years)

+32.5%▲favorable

formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1

e.g.($2,780M ÷ $681M) ^ (1÷5) − 1 = 32.5%

termsCAGR · ^ (exponent) · Revenue (net sales)

Operating margin (FY2025)

-2.2%

-0.2pt vs. 5 years ago

formulaoperating income ÷ revenue × 100

e.g.$-62M ÷ $2,780M × 100 = -2.2%

termsOperating income · Revenue (net sales)

ROE (FY2025)

4.5%▼caution

6-year average: 7.1%

As reported in the 10-K

P/B (FY2025 end)

14.05x

formulafiscal year-end closing price ÷ book value per share

e.g.$567.93 ÷ $40.43 = 14.05x

termsP/B · BVPS

Period-end (fiscal year-end) value, not today's P/B

EV/EBITDA (FY2025 end)

2,189.4x

formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)

e.g.($45,555M + $1,811M − $1,201M) ÷ ($-62M + $83M) = 2189.4x

termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)

Period-end (fiscal year-end) value, not today's multiple

  • ▲

    Revenue grew +32.5% a year over 5 years (strong growth)

    From $681M in FY2020 to $2.78B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.

  • ―

    Operating margin held roughly flat: -2.1% → -2.2%

    How much operating profit is left per $100 of revenue. It moved -0.2 points over 5 years — pricing power, cost control, and product mix all show up here.

  • ―

    Equity ratio is 46.3% (a middling level)

    The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).

  • ―

    Free cash flow was positive in 5 of 6 years

    Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.

  • ―

    ROE averaged 7.1% over 6 years (latest: 4.5%)

    How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.

09

Business modelSite analysis

Connected Devices

TASER energy devices and cartridges, Axon Body cameras, in-car and fixed cameras, drones and counter-drone (Dedrone) systems, VR training hardware, and extended warranties.

Connected Devices: how money and goods flow
  1. 01 what it draws on

    Inputs & resources

    • More than 5,100 full-time employees company-wide
    • Component suppliers
  2. 02 what it does

    Activities

    • Designing and building devices
    • Connecting devices to Axon's cloud software
  3. 03 who it serves

    Customers

    • Police, corrections, and public safety agencies
    • Enterprises and international governments
  4. 04 how money comes in

    How it earns

    • Device and cartridge sales
    • Extended warranties

Connected Devices: how it makes money

  • Revenue $1.58B (+29%) in 2025: TASER $914M, Personal Sensors $397M, Platform Solutions $266M.

Software and Services

Cloud software — Axon Evidence for digital evidence, Axon Records, Draft One and other AI Era Plan tools, Axon Fusus and Respond for real-time operations — plus professional services.

Software and Services: how money and goods flow
  1. 01 what it draws on

    Inputs & resources

    • Cloud platform and AI models
    • Data from connected devices
  2. 02 what it does

    Activities

    • Hosting evidence and records
    • Real-time operations and 911 software
  3. 03 who it serves

    Customers

    • Public safety agencies and enterprises
  4. 04 how money comes in

    How it earns

    • Multi-year SaaS subscriptions
    • Professional services

Software and Services: how it makes money

  • Revenue $1.20B (+40%) in 2025.
  • Annual recurring revenue $1.3B at year-end 2025, $1.6B by June 2026.

Government & regulation around the business

Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.

Axon sells mostly to government agencies and its TASER devices are regulated as firearms in some places.

  • Government as customer

    Government agency customers

    A significant portion of end users are government agencies that do not directly control their budgets.

    Supports and constrainsTouches: Customers · How it earns

    Source: Form 10-K (FY2025)

  • Trade & export rules

    Device and data regulation

    Laws cover privacy and data protection, regulation of conducted energy devices as firearms, and spectrum use.

    Constrains the businessTouches: Activities

    Source: Form 10-K (FY2025)

Revenue by segment (FY2025)

Unit: $M — bar length = revenue, (%) = share of total company revenue, margin = segment profit ÷ segment revenue × 100

  • Connected Devices

    1,577 (57%)

    profit 768 · margin 48.7%

  • Software and Services

    1,203 (43%)

    profit 891 · margin 74.1%

Source: Form 10-K (FY2025) — MD&A, gross margin by segment Profit is segment gross margin; the company reported an operating loss of $62M after $1.72B of operating expenses.

10

Where it earnsSite analysis

Many U.S.-listed companies earn most of their revenue outside the U.S. — this breaks down revenue by country/region so it's clear where the business actually makes its money.

Largest market (FY2025)

United States — 83% of revenue

Revenue by country / region (FY2025)

Unit: $M — bar length = revenue, (%) = share of total company revenue

  • United States

    2,305 (83%)
  • Other countries

    475 (17%)

Source: Form 10-K (FY2025) — MD&A, revenue by geography

11

Contract structureSite analysisShow

Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.

Axon sells hardware together with multi-year software subscriptions, so customers sign long contracts; future contracted bookings were $15.1 billion by mid-2026. Contracts in international and enterprise markets are often shorter than in U.S. state and local public safety.

  • Multi-year / recurring

    Software subscriptions

    Most of $1.20B Software and Services revenue

    Typical term: Multi-year SaaS agreements

    Net revenue retention 126% (Q2 2026).

  • Devices

    $1.58B (57%)

    Typical term: Device sales, accessories, and extended warranties

Source: Form 10-K (FY2025) — Item 1

12

Customers & suppliersSite analysis

Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.

Customers

Police, corrections, and other public safety agencies in the U.S. and abroad, plus enterprises.

Named by the company

None named in the 10-K or the company’s press releases.

What the filings disclose

  • 83% of 2025 revenue came from the United States. (Form 10-K (FY2025), MD&A)

Suppliers

Component and manufacturing suppliers for devices.

Named by the company

None named in the 10-K or the company’s press releases.

13

Competitors & peersSite analysis

Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.

Axon's 10-K names many competitors by product area — body and in-car cameras and evidence software, ALPR, 911 and real-time operations, and counter-drone — and calls these markets highly competitive. Key names are shown below.

Competitors named in the 10-K

Body cameras, in-car video, evidence software

The 10-K lists about 30 competitors in this area.

Automatic license plate recognition

911 and emergency communications

Counter-drone (Dedrone)

A fast-growing, fragmented market with dozens of competitors.

Source: Form 10-K (FY2025) — Item 1, Competition

Peer group the company chose

Executive compensation comparator group, from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.

Public technology companies selected by Semler Brossy with revenue of $435M–4B and market capitalization of $4B–65B, focusing on similar revenue growth.

Source: Proxy statement (DEF 14A, filed 2026-04-16) — Peer Comparator Group

Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.

14

M&A historySite analysisShow

Companies acquired over the last five years, plus older large acquisitions that still anchor a current business — what each was bought to do, and what happened afterward. From the 10-K, 8-Ks, and the company's press releases.

Axon expands its platform through acquisitions.

Cash spent on acquisitions, FY2021–FY2025: $1.31B (years not reported separately are excluded)

  1. Feb 2026

    Carbyne

    $625.0M base purchase price

    A cloud-native emergency communications and response (NG911) platform.

    Stated purpose (company)
    Extends Axon's offerings into the core call-handling layer of the NG911 workflow.

    Source: Form 10-K (FY2025) — Note 20; Item 1

  2. Oct 2024

    Dedrone

    Not stated here

    Counter-drone technology.

    Stated purpose (company)
    Not stated.

    Source: Form 10-K (FY2025) — Legal Proceedings

15

Six years of financialsFrom SEC data

Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.

Revenue over time

Unit: $M

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

Profit over time (operating → net)

Unit: $M

  • Operating income
  • Pretax income
  • Net income

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

Margins over time

Unit: %

  • Operating margin
  • Net margin

formulaoperating income ÷ revenue × 100

termsOperating income · Revenue (net sales)

formulanet income attributable to the company ÷ revenue × 100

termsNet income (attributable to the company)

Cash flow over time

Unit: $M (below zero = cash went out)

  • Operating CF
  • Investing CF
  • Free CF

formulacash flow from operations − capital expenditures

termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

Financial stability & capital efficiency

Unit: %

  • Equity ratio
  • ROE

formulatotal equity ÷ total assets × 100 (as reported in the 10-K)

termsStockholders’ equity · Total assets

formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)

termsNet income (attributable to the company) · Stockholders’ equity

Earnings per share (EPS) and dividend per share

Unit: $

  • EPS

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

Line itemFY202010-K on EDGAR ↗FY202110-K on EDGAR ↗FY202210-K on EDGAR ↗FY202310-K on EDGAR ↗FY202410-K on EDGAR ↗FY202510-K on EDGAR ↗
Income statement ($M)
Revenue6818631,1871,5612,0832,780
Operating income-14-1689315759-62
Pretax income-6-14119615738219
Net income (attributable)-2-60147176377125
Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100—26.8%37.5%31.5%33.4%33.5%
Operating margincalcoperating income ÷ revenue × 100-2.1%-19.5%7.8%10.0%2.8%-2.2%
Net margincalcnet income attributable to the company ÷ revenue × 100-0.3%-7.0%12.4%11.3%18.1%4.5%
Balance sheet ($M)
Total assets1,3811,6882,8523,4094,4757,000
Total equity9761,0501,2711,6162,3283,243
Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable——6746776801,811
Equity ratio70.7%62.2%44.6%47.4%52.0%46.3%
ROE-0.2%-5.9%12.7%12.2%19.1%4.5%
Cash flow ($M)
Operating CF38124235189408211
Investing CF-357253-83112-491-725
Financing CF299-17459841-451,252
Free cash flowcalccash flow from operations − capital expenditures-347518013033075
Cash and equivalents1553563545994551,201
Per share & other
EPS ($)-0.03-0.912.032.334.801.51
BVPS ($)15.3114.8117.7821.4630.3840.43
P/E (x)——81.7110.9123.8376.1
EV/EBITDA (x)calc(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)——104.9110.9427.82,189.4
P/B (x)calcfiscal year-end closing price ÷ book value per share8.0010.609.3312.0419.5614.05

P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.

Last 8 quarters

Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.

Quarter endedRevenueOperating incomeNet incomeDiluted EPS
2026-09-30$909M+27.8%$42M$57M$0.68
2026-06-30$904M+35.3%$47M$29M-18.5%$0.36
2026-03-31$807M+33.7%$29M$169M+92.4%$2.05
2025-12-31 †$797M+38.5%−$50M$3M-98.0%—
2025-09-30$711M−$2M−$2M$-0.03
2025-06-30$669M−$1M$36M$0.44
2025-03-31$604M−$9M$88M$1.08
2024-12-31 †$575M−$16M$135M—

† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.

16

Is ROIC above WACC?From SEC data

ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.

ROIC (FY2025)

-1.2%

formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)

e.g.$-62M × (1 − 21%) ÷ $4,031M × 100 = -1.2%

termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity

WACC (this site’s estimate)

12.06%

formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight

e.g.Equity weight: $45.55B ÷ ($45.55B + $1.81B) = 96.2%

e.g.Debt weight: $1.81B ÷ ($45.55B + $1.81B) = 3.8%

e.g.WACC: 12.4% × 96.2% + 5.2% × (1 − 21%) × 3.8% = 12.06%

termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization

ROIC − WACC

-13.3pt▼caution

Falling short of the cost of capital (ROIC > WACC in only 0 of 6 years)

formulaROIC − WACC (positive means the business earns more than its cost of capital)

termsROIC · WACC

How firm is this? With the equity risk premium ±1 point and beta ±0.2, WACC runs 9.9%–14.6% and ROIC − WACC runs −15.8 to −11.1 points. The sign holds across this range. This describes the latest year and does not predict future value creation.

WACC 12.06% is this site’s estimate under the assumptions below (not a figure the company has published)

Risk-free rate
4.95% (10-year Treasury, 2026-11-03)
β
1.35 (price-derived adjusted beta)
Equity risk premium
5.5%
Cost of equity
12.38%
Cost of debt
5.20%
Tax rate
21% (U.S. federal statutory rate (not enough data for an effective rate))
Capital structure (equity : debt)
96% : 4%
→ Change assumptions and recalculate

ROIC over time, vs. WACC

Unit: % — bars = each period's ROIC, horizontal line = latest WACC. Bars above the line are green, below are red

  • ROIC (above WACC)
  • ROIC (below WACC)
  • WACC 12.06%

formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)

termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity

formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight

termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization

Try different WACC assumptions

β and the equity risk premium are estimates with a real range of plausible values — move the sliders to check whether ROIC > WACC still holds. The risk-free rate starts at the 10-year Treasury yield on 2026-11-03 (U.S. Treasury).

Initial β: 1.35 (price-derived adjusted beta. Raw β 1.52, R² 0.13, 130 weeks)

formula0.67 × β + 0.33 (β = the slope of weekly stock returns regressed on weekly market returns)

e.g.0.67 × 1.517 + 0.33 = 1.346

termsβ (beta)

Period 2024-05-10–2026-11-04, using S&P 500 ETF (SPY) as the market proxy. Source: Yahoo Finance price history.

Cost of equity12.38%

formularisk-free rate + β × equity risk premium

e.g.5.0% + 1.35 × 5.5% = 12.4%

termsCAPM · Risk-free rate · β (beta) · Equity risk premium (market risk premium)

Market value of equity$45.55B

formulafiscal year-end closing price × shares outstanding (= market cap)

termsMarket capitalization · Market value of equity

Interest-bearing debt$1.81B
Cost of debt5.20%

formulainterest expense ÷ interest-bearing debt × 100 (clamped to 0–10%; falls back to the risk-free rate if there’s no debt)

termsInterest-bearing debt · Risk-free rate

Capital structure (equity weight : debt weight)96% : 4%

17

What the price implies (DCF)From SEC data

A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.

Growth the price implies (price on 2026-11-04)

11.8%

Perpetual FCF growth: g = r − FCF ÷ EV = 12.1% − 0.2%

Past FCF growth (FY2020–FY2025)

—

Not computable (FCF not positive in both years)

Past revenue growth (FY2020–FY2025)

+32.5%

Compound annual rate, 5 years

Inputs (FY2025): free cash flow $75M (operating CF − capex); enterprise value $34.4B = market cap $34.29B (latest close, 2026-11-04) + debt $1.81B − cash and short-term investments $1.71B; r = WACC of 12.1% using this page’s default assumptions (β 1.35, risk-free 5.0%, market premium 5.5%).

Three WACC scenarios

The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.

Try your own assumptions

V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.

Theoretical enterprise value

$25.03B

FCF $75M ÷ (12.1% − 11.8%)

Theoretical ÷ actual enterprise value

0.73x

Below 1x: these assumptions value the business below the market did

How sensitive the answer is

Theoretical ÷ actual enterprise value for each combination of r and g.

g \ r10.1%11.1%12.1%13.1%14.1%
0%0.02x0.02x0.02x0.02x0.02x
2%0.03x0.02x0.02x0.02x0.02x
4%0.04x0.03x0.03x0.02x0.02x
6%0.05x0.04x0.04x0.03x0.03x
8%0.10x0.07x0.05x0.04x0.04x

A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.

18

Earnings qualityFrom SEC dataShow

The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.

  • ✓

    Operating CF ÷ net income: averages 1.36x

    Profit is backed by cash coming in.

  • ✓

    Accrual ratio (latest): -1.5%

    A small share of profit rests on accounting estimates.

  • !

    Core-earnings share (operating income ÷ pretax income): -327%

    Non-operating items (interest income, equity-method gains, other income/expense) are having a bigger effect.

Operating CF vs. net income

Unit: $M — operating CF above net income means profit is backed by cash

  • Operating CF
  • Net income

formulacash flow from operations ÷ net income attributable to the company

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formula(net income − operating CF) ÷ average total assets × 100

termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

Profit bridge (FY2025)

Unit: $M — what moved profit from operating income to net income

  • Profit (each stage)
  • Pushed profit up
  • Pushed profit down

formulaoperating income ÷ income before income taxes × 100

termsOperating income · Income before income taxes (pretax income)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-25

Receivables & inventory days

Unit: days — days grow when receivables or inventory build up faster than sales

  • Days inventory outstanding

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

termsInventory · Cost of revenue (COGS)

Worked examples (latest period)

formulacash flow from operations ÷ net income attributable to the company

e.g.$211M ÷ $125M = 1.70x

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formulaoperating income ÷ income before income taxes × 100

e.g.$-62M ÷ $19M × 100 = -327%

termsOperating income · Income before income taxes (pretax income)

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

e.g.($265M + $342M) ÷ 2 ÷ $1,121M × 365 = 99 days

termsInventory · Cost of revenue (COGS)

19

Who holds the sharesFrom SEC dataShow

How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.

Institutions, insiders and everyone else, 13F holdings as of 2026-06-30

“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.

Held by 13F filers
89.1%
Directors & officers (shares)
4.2%
Everyone else (est.)
6.7%

individuals and other non-13F holders

Directors & officers (voting power)
4.2%

no separate voting figure; shown as shares

Institutional-ownership rank
207 of 416

1 = most institutional; 50% of covered companies have more

Beta (adjusted)
1.35

above 1 = swings more than the market

  • 72.4M shares reported by 1,128 13F filers ÷ 81.2M shares outstanding on 2026-07-31. Option positions are excluded.
  • Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days.
  • A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.

Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-04-16 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-07-31)

20

Strengths & weaknessesSite analysis

Strengths

  1. 1. Fast, sustained growth

    Revenue grew from $1.19B (2022) to $2.78B (2025); Q2 2026 was the 10th consecutive quarter of growth above 30%.

    Evidence: SEC EDGAR XBRL; Q2 2026 shareholder letter

  2. 2. Recurring software revenue

    Annual recurring revenue of $1.6B (+39%) and net revenue retention of 126% in Q2 2026.

    Evidence: Q2 2026 shareholder letter

  3. 3. Large contracted backlog

    Future contracted bookings of $15.1B (+41%) at mid-2026.

    Evidence: Q2 2026 shareholder letter

  4. 4. Integrated ecosystem

    Devices and software are designed to work together, and Axon's software also supports devices from other vendors.

    Evidence: Form 10-K (FY2025), Item 1

Weaknesses

  1. 1. Thin GAAP profitability

    An operating loss of $62M in 2025 as SG&A rose to 37% of revenue and R&D to 25%.

    Evidence: Form 10-K (FY2025)

  2. 2. High valuation multiple

    P/E at the end of fiscal 2025 was about 376x, based on EPS of $1.51.

    Evidence: SEC EDGAR XBRL; site calculation

  3. 3. Reliance on government budgets

    Customers are mainly public agencies subject to procurement rules and budgets.

    Evidence: Form 10-K (FY2025), Risk Factors

21

What draws investors to itSite analysis

Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.

P/E (FY2025)

376.1x

Price at fiscal year-end ÷ diluted EPS

Dividend yield (FY2025)

—

Dividends per share ÷ fiscal year-end price

Payout ratio (FY2025)

—

Dividends per share ÷ diluted EPS

FCF yield (FY2025)

0.2%

(Operating CF − capex) ÷ market cap

  1. 1. Public safety operating system

    Hardware drives adoption of recurring software, with AI tools such as Draft One growing quickly.

    What has to hold
    Agencies keep upgrading to premium software bundles.
    The other side
    GAAP profits are small relative to the valuation.

    Evidence: Form 10-K (FY2025); Q2 2026 shareholder letter

  2. 2. New markets

    International and enterprise bookings roughly tripled in Q2 2026, and Axon is moving into 911 and counter-drone.

    What has to hold
    New markets scale like U.S. policing.
    The other side
    Those contracts are often shorter.

    Evidence: Q2 2026 shareholder letter

Axon doesn't pay a dividend.

22

ResilienceSite analysisShow

How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.

1. Financial buffer (FY2025)

Cash & short-term investments ÷ debt due within a year

21.2x

$1.71B vs. $81M

Interest coverage (operating income ÷ interest expense)

-0.7x

−$62M vs. $94M

Free cash flow ÷ dividends paid

—

2. Worst year in the record, and the recovery

FigureWorst year-over-year changeBack to the prior level?
RevenueNo decline in the record—
Operating income-206.0% in FY2025 ($59M → −$62M)Not yet, as of FY2025

Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.

3. Business resilience (from the 10-K)

  • Contracted revenue

    $15.1B of future contracted bookings at mid-2026.

    Source: Q2 2026 shareholder letter

  • Liquidity

    $1.2B of cash and $505M of short-term investments at year-end 2025, plus $1.15B of convertible notes raised in September 2026.

    Source: SEC EDGAR XBRL; 8-K filed 2026-09-21

  • Public budgets

    Demand depends on government funding cycles.

    Source: Form 10-K (FY2025), Risk Factors

24

Risks (including geopolitical)Site analysis

Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.

Risk map

Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).

Impact
High
Med
234
1
Low
LowMedHigh

Likelihood →

"Company disclosure" vs. "this site’s assessment"

The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.

Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.

  1. 1Competition & technology shift

    Many competitors

    Company disclosure (summarized from the 10-K)
    Competition in body cameras, in-car video, ALPR, 911 software, and counter-drone from companies such as Motorola Solutions, Flock Safety, Genetec, and Axis Communications.
    Company’s stated mitigation
    Integrated hardware-software ecosystem.
    This site’s assessment
    Impact Med / Likelihood High
  2. 2Law & regulation

    Government procurement and regulation

    Company disclosure (summarized from the 10-K)
    Federal, state, local, and foreign procurement laws apply, and some jurisdictions restrict TASER devices; export controls also apply.
    Company’s stated mitigation
    Not stated.
    This site’s assessment
    Impact Med / Likelihood Med
  3. 3Governance & quality

    Litigation and product liability

    Company disclosure (summarized from the 10-K)
    Patent suits (e.g., Airspace Systems v. Dedrone) and claims involving products.
    Company’s stated mitigation
    Not stated.
    This site’s assessment
    Impact Med / Likelihood Med
  4. 4M&A & integration

    Acquisitions

    Company disclosure (summarized from the 10-K)
    Integrating Dedrone, Prepared, and Carbyne into the platform.
    Company’s stated mitigation
    Not stated.
    This site’s assessment
    Impact Med / Likelihood Med

25

What changed in the risk factorsFrom SEC data

Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.

New or substantially reworded (8)

  • • Uncertainties with complex U.S. federal, state and local and foreign procurement laws and regulations could cause us to incur costs that could have a material adverse effect on our business, financial position, results of operations and cash flow.

  • Acquisitions and investments may present unforeseen operating, financial, or compliance challenges. Read more

    Many of these challenges may arise from actions, omissions, business practices, contractual arrangements, or operational decisions of the acquired business or investee entity that occurred prior to or independently of our ownership or involvement. Integrating acquired personnel, operations, systems, technologies, and products or effectively managing the combined business can be complex, costly, and disruptive. Our ability to identify and assess material risks and liabilities through due diligence may be limited, particularly where sellers restrict access to information, transaction timelines are compressed, or we acquire a non-controlling interest. Anticipated benefits of such transactions may not materialize due to factors such as:

  • • inability to integrate or profitably benefit from acquired products, technologies (including AI and machine learning models), or businesses; Read more

    inherited risks associated with AI or machine learning models (including model performance limitations, bias, explainability challenges, or reliance on training data) that may be incomplete, inaccurate, or subject to regulatory restrictions;

  • • unanticipated costs, liabilities, or risks related to litigation (including intellectual property claims and disputes, government inquiries, or regulatory actions); Read more

    exposure to actual or alleged intellectual property infringement, misappropriation, or other intellectual property claims arising from the technologies, products, software, data, or business practices of an acquired company or an entity in which we hold a minority investment (including claims that pre-date our acquisition or investment, discontinuation of products, modification of technologies, commencement of licensing arrangements on unfavorable terms, or payment of damages, settlements, or ongoing royalties);

  • In the case of minority or non-controlling investments, we may have limited ability to influence the strategic direction, governance, regulatory compliance, risk management, or operations of the investee business, may be subject to conflicts with other shareholders or founders, and may receive less timely or less complete information regarding the investee’s performance or risks.

  • We may finance acquisitions or investments through the issuance of equity or debt. Read more

    The issuance of equity could dilute existing shareholders, and the issuance of debt could reduce liquidity or increase leverage and interest expense. Debt financing activities may also include restrictive covenants or repayment obligations that limit operational flexibility or our ability to pursue additional strategic transactions.

  • Significant acquisitions typically result in the recognition of goodwill and other intangible assets. Read more

    If the acquired business does not perform as expected, we may be required to record non-cash impairment charges, which could materially affect our operating results and financial condition.

  • Our suppliers may themselves be subject to export controls or other trade restrictions on the materials and components they provide, including controls imposed by their countries of origin. Read more

    In addition, increased use by the PRC of foreign “entity lists,” modeled in part on U.S. and other Western trade controls, could restrict Axon’s ability to import components or materials sourced from the PRC. Components or other items that are incorporated into our weapons or defense articles may also become subject to export controls in their originating jurisdictions based on their ultimate end use, which could further disrupt supply chains, delay production, or increase costs.

No longer in the text (4)

  • Our future success depends on our ability to expand sales through direct sales and distributors and our inability to increase direct sales or recruit new distributors would negatively affect our sales.

  • Our distribution strategy is to pursue sales through multiple channels primarily through direct sales and independent distributors. Read more

    We focus on direct sales to larger agencies and our inability to grow sales to these agencies in this manner would materially adversely affect our business prospects, operating results, and financial condition. In addition, our inability to establish relationships with and retain distributors who we believe can successfully sell our products would materially adversely affect our business prospects, operating results, and financial condition. If we do not competitively price our products, meet the requirements of our distributors or end-users, provide adequate marketing support, or comply with the terms of our distribution arrangements, our distributors may fail to aggressively market our products or may terminate their relationships with us. These…

  • In certain states and foreign jurisdictions, we have chosen to sell directly with law enforcement customers rather than through established distribution channels. Read more

    However, some of our customers may have strong working relationships with distributors, and we may face resistance to this change. Failure to overcome this resistance and successfully establish direct relationships with our customers could negatively impact sales, or our competitors may be better positioned by continuing to sell through distributors, which could adversely affect our business prospects, operating results and financial condition.

  • • exposure to new regulations related to the acquired products, technologies, or business that are unexpectedly burdensome, negatively impact existing products, technologies or business, or require significant investment in order to achieve compliance;

21 more paragraphs differ; the filings below have the full text.

Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 25, 2026 ↗ with the 10-K filed Feb 28, 2025 ↗.

26

What to watch going forwardSite analysis

  • ARR growth and net revenue retention.
  • Profitability as R&D and sales spending rise.
  • Axon 911 adoption after the Carbyne acquisition.
  • International and enterprise bookings.
  • 2026 revenue growth guidance of 32–34%.

27

Source documentsShow

This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.

Last updated

Analysis last edited: October 10, 2026 · Financial data fetched: October 17, 2026 10:06 (SEC EDGAR) · Source 10-K filed: February 25, 2026

Built on10-K FY2025 · filed 2026-02-25

Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

This page is this site’s own analysis based on public information, and does not represent Axon Enterprise, Inc.’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.